OBJECTIVES: To evaluate symptoms and signs of genital irritation, vaginal leakage and acceptability of polystyrene sulfonate (PSS), which is being studied as a vaginal contraceptive and microbicide. METHODS: Forty-nine women applied 2.5 mL of either 5% PSS, 10% PSS, PSS vehicle, or Conceptrol (a marketed spermicidal product containing 4% nonoxynol-9) for 6 consecutive days. RESULTS: All women completed the study except one in the Conceptrol group who experienced vaginal symptoms after her first use and was discontinued. After both the first use and after all uses, irritation was seen among more women in the Conceptrol group than in the PSS groups, reaching statistical significance with regard to any evidence of irritation, signs of irritation and product-related irritation. There were no adverse events that were serious, unexpected and related to product use in any group. The 5% concentration of PSS may be preferable in terms of leakage and acceptability. CONCLUSION: The results suggest that PSS has a safety profile comparable to that of the marketed nonoxynol-9 product, Conceptrol, and appears to be associated with less genital irritation.
RCT Entities:
OBJECTIVES: To evaluate symptoms and signs of genital irritation, vaginal leakage and acceptability of polystyrene sulfonate (PSS), which is being studied as a vaginal contraceptive and microbicide. METHODS: Forty-nine women applied 2.5 mL of either 5% PSS, 10% PSS, PSS vehicle, or Conceptrol (a marketed spermicidal product containing 4% nonoxynol-9) for 6 consecutive days. RESULTS: All women completed the study except one in the Conceptrol group who experienced vaginal symptoms after her first use and was discontinued. After both the first use and after all uses, irritation was seen among more women in the Conceptrol group than in the PSS groups, reaching statistical significance with regard to any evidence of irritation, signs of irritation and product-related irritation. There were no adverse events that were serious, unexpected and related to product use in any group. The 5% concentration of PSS may be preferable in terms of leakage and acceptability. CONCLUSION: The results suggest that PSS has a safety profile comparable to that of the marketed nonoxynol-9 product, Conceptrol, and appears to be associated with less genital irritation.
Authors: Jose A Simoes; Diane M Citron; Alla Aroutcheva; Robert A Anderson; Calvin J Chany; Donald P Waller; Sebastian Faro; Lourens J D Zaneveld Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191
Authors: Lourens J D Zaneveld; Donald P Waller; Robert A Anderson; Calvin Chany; William F Rencher; Kenneth Feathergill; Xiao-Hui Diao; Gustavo F Doncel; Betsy Herold; Morris Cooper Journal: Biol Reprod Date: 2002-04 Impact factor: 4.285
Authors: R A Anderson; K Feathergill; X Diao; M Cooper; R Kirkpatrick; P Spear; D P Waller; C Chany; G F Doncel; B Herold; L J Zaneveld Journal: J Androl Date: 2000 Nov-Dec
Authors: N D Christensen; C A Reed; T D Culp; P L Hermonat; M K Howett; R A Anderson; L J Zaneveld Journal: Antimicrob Agents Chemother Date: 2001-12 Impact factor: 5.191
Authors: C Mauck; D H Weiner; S Ballagh; M Creinin; D F Archer; J Schwartz; H Pymar; J J Lai; M Callahan Journal: Contraception Date: 2001-12 Impact factor: 3.375
Authors: Robert A Anderson; Alla Aroutcheva; Kenneth A Feathergill; Amillia B Anderson Journal: Probiotics Antimicrob Proteins Date: 2009-03-04 Impact factor: 4.609
Authors: Courtney A Schreiber; Leslie A Meyn; Mitchell D Creinin; Kurt T Barnhart; Sharon L Hillier Journal: Obstet Gynecol Date: 2006-01 Impact factor: 7.661
Authors: Kathleen M Morrow; Joseph L Fava; Rochelle K Rosen; Sara Vargas; Candelaria Barroso; Anna L Christensen; Cynthia Woodsong; Lawrence Severy Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Frieda M Behets; Abigail Norris Turner; Kathleen Van Damme; Ny Lovaniaina Rabenja; Noro Ravelomanana; Teresa A Swezey; April J Bell; Daniel R Newman; D'Nyce L Williams; Denise J Jamieson Journal: Sex Transm Dis Date: 2008-09 Impact factor: 2.830
Authors: Robert A Anderson; David Brown; Erin M Jackson; Kenneth A Feathergill; James W Bremer; Ralph Morack; Richard G Rawlins Journal: ISRN Obstet Gynecol Date: 2010-11-28